Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

By afschroeder • February 17, 2026

Oshima A, Serruys PW, Garg S, McEvoy JW, Wood DA, Doenst T, Taggart DP, Puskas JD, Shajahan A, Sharif F, Miyashita K, Tobe A, Tsai TY, Revaiah PC, Dunne F, Mehran R, Budoff MJ, Kastelein JJ, Stroes ESG, Khamis R, Koenig W, Onuma Y. Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation. EuroIntervention. 2026 Feb 16;22(4):202-223. doi: 10.4244/EIJ-D-25-00598. PMID: 41697657.

Tags: Cardiology/Epi, Harbor UCLA, Publications

Related Posts

Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial

Ells Z, Meyer C, Kimura K, Wilhalme H, Cao M, Ludwig VB, Unterrainer LM, Sennung D, Nabong R, Felix C, Valle LF, Daley A, Czernin[...]

Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum

Hemeryck J, De Moor N, Ezzat D, Khan RR, Vandergrift N, Levine LD, Rouse C, Theilen LH, Bairey Merz CN, Yee LM, Chung J, Bello[...]

Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction

Jacobs JA, Greene T, Vanneman ME, Kean J, Carter SJ, Shah KS, Pandey A, Derington CG, Zheutlin AR, Fang J, Stehlik J, Fonarow GC, Bress[...]